These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

184 related items for PubMed ID: 24841832

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. JAK2 inhibitor TG101348 overcomes erlotinib-resistance in non-small cell lung carcinoma cells with mutated EGF receptor.
    Zhang FQ, Yang WT, Duan SZ, Xia YC, Zhu RY, Chen YB.
    Oncotarget; 2015 Jun 10; 6(16):14329-43. PubMed ID: 25869210
    [Abstract] [Full Text] [Related]

  • 4. Combined Erlotinib and Cetuximab overcome the acquired resistance to epidermal growth factor receptors tyrosine kinase inhibitor in non-small-cell lung cancer.
    Wang M, Zhao J, Zhang LM, Li H, Yu JP, Ren XB, Wang CL.
    J Cancer Res Clin Oncol; 2012 Dec 10; 138(12):2069-77. PubMed ID: 22821179
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Combined vascular endothelial growth factor receptor and epidermal growth factor receptor (EGFR) blockade inhibits tumor growth in xenograft models of EGFR inhibitor resistance.
    Naumov GN, Nilsson MB, Cascone T, Briggs A, Straume O, Akslen LA, Lifshits E, Byers LA, Xu L, Wu HK, Jänne P, Kobayashi S, Halmos B, Tenen D, Tang XM, Engelman J, Yeap B, Folkman J, Johnson BE, Heymach JV.
    Clin Cancer Res; 2009 May 15; 15(10):3484-94. PubMed ID: 19447865
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Addition of bevacizumab enhances antitumor activity of erlotinib against non-small cell lung cancer xenografts depending on VEGF expression.
    Li H, Takayama K, Wang S, Shiraishi Y, Gotanda K, Harada T, Furuyama K, Iwama E, Ieiri I, Okamoto I, Nakanishi Y.
    Cancer Chemother Pharmacol; 2014 Dec 15; 74(6):1297-305. PubMed ID: 25344762
    [Abstract] [Full Text] [Related]

  • 10. Apatinib enhances antitumour activity of EGFR-TKIs in non-small cell lung cancer with EGFR-TKI resistance.
    Li F, Zhu T, Cao B, Wang J, Liang L.
    Eur J Cancer; 2017 Oct 15; 84():184-192. PubMed ID: 28822888
    [Abstract] [Full Text] [Related]

  • 11. Impact of bevacizumab in combination with erlotinib on EGFR-mutated non-small cell lung cancer xenograft models with T790M mutation or MET amplification.
    Furugaki K, Fukumura J, Iwai T, Yorozu K, Kurasawa M, Yanagisawa M, Moriya Y, Yamamoto K, Suda K, Mizuuchi H, Mitsudomi T, Harada N.
    Int J Cancer; 2016 Feb 15; 138(4):1024-32. PubMed ID: 26370161
    [Abstract] [Full Text] [Related]

  • 12. Targeting the epidermal growth factor receptor in non-small cell lung cancer cells: the effect of combining RNA interference with tyrosine kinase inhibitors or cetuximab.
    Chen G, Kronenberger P, Teugels E, Umelo IA, De Grève J.
    BMC Med; 2012 Mar 21; 10():28. PubMed ID: 22436374
    [Abstract] [Full Text] [Related]

  • 13. Dual MET-EGFR combinatorial inhibition against T790M-EGFR-mediated erlotinib-resistant lung cancer.
    Tang Z, Du R, Jiang S, Wu C, Barkauskas DS, Richey J, Molter J, Lam M, Flask C, Gerson S, Dowlati A, Liu L, Lee Z, Halmos B, Wang Y, Kern JA, Ma PC.
    Br J Cancer; 2008 Sep 16; 99(6):911-22. PubMed ID: 19238632
    [Abstract] [Full Text] [Related]

  • 14. Inhibiting proliferation of gefitinib-resistant, non-small cell lung cancer.
    Sudo M, Chin TM, Mori S, Doan NB, Said JW, Akashi M, Koeffler HP.
    Cancer Chemother Pharmacol; 2013 May 16; 71(5):1325-34. PubMed ID: 23515752
    [Abstract] [Full Text] [Related]

  • 15. YM155 sensitizes non-small cell lung cancer cells to EGFR-tyrosine kinase inhibitors through the mechanism of autophagy induction.
    Dai CH, Shu Y, Chen P, Wu JN, Zhu LH, Yuan RX, Long WG, Zhu YM, Li J.
    Biochim Biophys Acta Mol Basis Dis; 2018 Dec 16; 1864(12):3786-3798. PubMed ID: 30315932
    [Abstract] [Full Text] [Related]

  • 16. Continuous inhibition of epidermal growth factor receptor phosphorylation by erlotinib enhances antitumor activity of chemotherapy in erlotinib-resistant tumor xenografts.
    Iwai T, Moriya Y, Shirane M, Fujimoto-Ouchi K, Mori K.
    Oncol Rep; 2012 Apr 16; 27(4):923-8. PubMed ID: 22209766
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Protein tyrosine kinase 2: a novel therapeutic target to overcome acquired EGFR-TKI resistance in non-small cell lung cancer.
    Tong X, Tanino R, Sun R, Tsubata Y, Okimoto T, Takechi M, Isobe T.
    Respir Res; 2019 Dec 02; 20(1):270. PubMed ID: 31791326
    [Abstract] [Full Text] [Related]

  • 19. Antitumor activity of HM781-36B, a highly effective pan-HER inhibitor in erlotinib-resistant NSCLC and other EGFR-dependent cancer models.
    Cha MY, Lee KO, Kim M, Song JY, Lee KH, Park J, Chae YJ, Kim YH, Suh KH, Lee GS, Park SB, Kim MS.
    Int J Cancer; 2012 May 15; 130(10):2445-54. PubMed ID: 21732342
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.